Ever wonder why our HLA specified cancer therapies are only for HLA02:01 thus far? @possuhuanglab.bsky.social presents the scope of the problem at the inaugural @stanford-cancer.bsky.social AI and Cancer Research Symposium 🧬

Introducing SLAE, our new framework to represent all-atom protein structures with residue local chemical environment tokens!
SLAE reasons over atomic interactions to recover structures and residue pairwise energetics, yielding a generalizable, physics-informed latent space. (1/8)

💻 Sampling and training code for Protpardelle-1c is now available: github.com/ProteinDesig...

Feedback and requests are welcome!

We have a new collection of protein structure generative models which we call Protpardelle-1c. It builds on the original Protpardelle and is tailored for conditional generation: motif scaffolding and binder generation.

SHAPES now published in Cell Systems!

All-atom fixed backbone protein sequence design with FAMPNN

@richardshuai.bsky.social Talal Widatalla @possuhuanglab.bsky.social @brianhie.bsky.social

www.biorxiv.org/content/10.1...

I'm organizing a Keystone symposium, along with Liz Kellogg and @possuhuanglab.bsky.social, on machine learning and macromolecules. Mar 23-26 in Keystone, Colorado. We have a great lineup and deadlines are coming up soon!

A framework for evaluating how well generative models of protein structure match the distribution of natural structures.

@possuhuanglab.bsky.social

www.biorxiv.org/content/10.1...

New preprint from our group! We propose SHAPES, a set of metrics to quantify the distributional coverage of generative models of protein structures with embeddings at different structural hierarchies and quantify undersampling / extrapolation behaviors.

This is a clever way to use synthetic biology: taking a toxin that overactivate the immune system (superantigen), rationally modify its core components and transform it into a platform of immunotherapy agents.
Congratulations to @haotiandu.bsky.social and @possuhuanglab.bsky.social on the 2 papers!

Checkout out these two bombshell papers from @possuhuanglab.bsky.social @stanfordmedicine.bsky.social, computational design of antigen-specific binders to MHC-I or -II, with applications to next gen targeted therapeutics 🤯

Science in 60 Seconds: Haotian Du, PhD student with Possu Huang’s lab, explains her research on creating novel proteins that expands the possibilities for detecting more cancer types.
@possuhuanglab.bsky.social @haotiandu.bsky.social

Incredible work from BioE Professor’s Possu Huang Lab @possuhuanglab.bsky.social @haotiandu.bsky.social - pioneering novel proteins with new structures and functions, unlocking new possibilities for detecting more cancer types. Congratulations!

Excited to share that TRACeR stories are out🙌

A new system, TRACeR-I, targets peptides on MHC I molecules with high precision, enabling specific tumor and virus cell killing.

It powers CAR-T and BiTE therapies, showing potential to transform cancer and infectious disease treatment.

www.nature.com/articles/s41...

1/ In two back-to-back papers, we present our de novo TRACeR platform for targeting MHC-I and MHC-II antigens

TRACeR for MHC-I: go.nature.com/4gcLzn5
TRACeR for MHC-II: go.nature.com/4gj5OQk